You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Evolving Anticoagulation in AF and VTE

There is strong evidence supporting the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in improving thromboembolic outcomes across a range of populations. Despite guideline recommendations for NOACs for the treatment of atrial fibrillation (AF) and venous thromboembolism (VTE), they are still widely underutilized or inappropriately applied. The Clinical Advances in Evolving Anticoagulation in AF and VTE is designed to update healthcare professionals on effective anticoagulation therapy in patients at risk for stroke or VTE.

Supported by an independent educational grant from

Daiichi-Sankyo Europe GmbH

CME Activities

Polling Question

Related Resources

Downloadable Slide Kits

Anticoagulation in Patients with Atrial Fibrillation Undergoing Catheter Ablation


Managing VTE in Patients with Cancer


Evolving Anticoagulation in AF and VTE

Secondary Stroke Prevention in AF


Evolving Anticoagulation in AF and VTE

Sex Differences in Stroke Prevention


Evolving Anticoagulation in AF and VTE

Factors to Consider When Selecting a NOAC and Dosing Considerations


Stroke Prevention in AF

A Review of Non-VKA Oral Anticoagulants


New Oral Anticoagulants and VTE Management

Overview of clinical trial data for novel oral anticoagulants.


Clinical Articles

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. 

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. 

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. 

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) 

Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. 

Edoxaban versus warfarin in patients with atrial fibrillation. 

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. 

Related Links

See All

Steering Committee

Raffaele De Caterina, MD, PhD

Professor of Cardiology
Director, University Cardiology Division
Pisa University Hospital
University of Pisa
Pisa, Italy

Hans-Christoph Diener, MD, PhD

Senior Professor of Clinical Neurosciences
Department of Neurology and Stroke Center
University Hospital Essen
University Duisburg
Essen, Germany

Robert P. Giugliano, MD

Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States

Andreas Goette, MD

Professor of Medicine
Department of Cardiology and Intensive Care Medicine
St. Vincenz Hospital
Paderborn, Germany

Yukihiro Koretsune, MD, PhD

General Institute for Clinical Research
Osaka National Hospital
Osaka, Japan

Gary Raskob, PhD

Regents Professor, Medicine and Epidemiology
Dean, College of Public Health
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States

Jeffrey Weitz, MD, FRCP

Professor of Medicine and Biochemistry
Hamilton, Ontario, Canada